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Brain tumour stem celle group of neoplasms that continue to present a formidable challenge in our
attempt to achieve curable intervention. Our conceptual framework of human brain cancer has been redrawn
in the current decade. There is a gathering acceptance that brain tumour formation is a phenotypic outcome
of dysregulated neurogenesis, with tumours viewed as abnormally differentiated neural tissue. In relation,
there is accumulating evidence that brain tumours, similar to leukaemia and many solid tumours, are
organized as a developmental hierarchy which is maintained by a small fraction of cells endowed with many
shared properties of tissue stem cells. Proof that neurogenesis persists throughout adult life, compliments
this concept. Although the cancer cell of origin is unclear, the proliferative zones that harbour stem cells in
the embryonic, post-natal and adult brain are attractive candidates within which tumour-initiation may
ensue. Dysregulated, unlimited proliferation and an ability to bypass senescence are acquired capabilities of
cancerous cells. These abilities in part require the establishment of a telomere maintenance mechanism for
counteracting the shortening of chromosomal termini. A strategy based upon the synthesis of telomeric
repeat sequences by the ribonucleoprotein telomerase, is prevalent in ∼90% of human tumours studied,
including the majority of brain tumours. This review will provide a developmental perspective with respect
to normal (neurogenesis) and aberrant (tumourigenesis) cellular turnover, differentiation and function.
Within this context our current knowledge of brain tumour telomere/telomerase biology will be discussed
with respect to both its developmental and therapeutic relevance to the hierarchical model of brain
tumourigenesis presented by the cancer stem cell paradigm.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
1.1. Characteristics of intracranial neoplasms
Of all solid cancers, brain tumours have the poorest survival and
highest morbidity rates. Although frequently considered collectively,
brain tumours represent a diverse range of tumour types affecting
both children and adults. Tumours of the brain account for less than
2% of all malignancies, yet now approach leukaemia as the leading
cause of cancer-related death in children and the fourth leading cause
in adults [1]. The diversity of brain tumour type is a reﬂection of the
histological complexity of the central nervous system (CNS) and can
present with glial or neuronal phenotypes or a mixture of cell types.
Medulloblastoma and supratentorial primitive neuroectodermal
tumours (sPNET) are World Health Organization (WHO) grade IV
embryonal tumours, resulting from the transformation of primitive
neuroectodermal cells. The medulloblastoma is a malignant and
invasive tumour with a relatively poor prognosis and represents the
most commonmalignant brain tumour in children. It is predominately. Rahman).
ll rights reserved.neuronal in nature and typically located in the cerebellum. In contrast
the rarer sPNETs are more commonly found in the cerebral hemi-
spheres and consist of poorly differentiated neuroepithelial cells
which confer poor prognosis, especially in children. Despite both
being classiﬁed as Grade IV tumours, sPNETs have a signiﬁcantly
worse prognosis [2].
Also classiﬁed as a grade IV tumour by the WHO, glioblastoma
multiforme (GBM) represents themostmalignant and aggressive form
of glioma, arising in the subcortical white matter as either a primary
neoplasm, or from themalignant progression of a lowgrade glioma [3].
Typically seen in adults, prognosis is extremely poor as the diffuse
distribution throughout the brainmakes surgical resection difﬁcult [4].
Ependymoma are typically classiﬁed as glial tumours, however it is
currently debated as to whether ependymoma may actually reﬂect a
separate entity. Composed of neoplastic ependymal cells, the
ependymoma is usually located along the ventricular system of the
paediatric or adolescent brain whereas spinal sites are more
commonly seen in adults. Prognosis is varied and is dependent on
surgical resection [5,6].
Although an understanding of human brain cancer pathogenesis
has increased in recent decades, insufﬁcient knowledge of the
molecular, genetic and cellular alterations and mechanisms is at the
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prognostic capabilities. As a result, bio-centred and target-speciﬁc
brain tumour therapy has not yet been forthcoming.
1.2. Neuro-developmental biology
The CNS is a highly complex structure which develops from a
restricted number of extensively plastic cells that proliferate and
acquire regional identities in space and time to produce a diverse
repertoire of cell types. Collectively, these cells are deﬁned as neural
stem cells (NSCs) on the basis of their potential to differentiate into
mature neurons and glia (astrocytes and oligodendrocytes) and their
ability to self-renew in vitro. This operational deﬁnition does not
however, necessarily reﬂect the function of NSCs in vivo and it remains
uncertain whether the cell type(s) exhibiting ‘stemness’ in vitro
faithfully represents the cell exhibiting ‘stemness’ in vivo.
Mammalian developmental neuro-biology now entertains an
integrated view of NSCs whereby neuroepithelial cells comprising
the neural tube of the developing embryo, give rise ﬁrst to radial glia,
which then transform into astrocyte-like adult multipotent stem cells
or directly into mature ependymal cells lining the walls of the lateral
ventricles, the latter of which are post-mitotic in the adult brain [7].
Radial glia arise from neuroepithelial cells throughout the primitive
CNS at the beginning of neurogenesis and represent the predominant
neuronal progenitor [8]. These cells characteristically display a radial
morphology and a mixed primitive cell/glial immunophenotype. In
mammals, radial glial cells disappear from the brain soon after birth,
with a closely-related astrocyte-like cell taking the role as NSC
thereafter. The belief that the genesis of new CNS cells is a rare event
in the adult mammalian brain was established dogma until recently.
Two constitutively active germinative layers are now known to reside
in the adult brain: the subventricular zone (SVZ) associated with the
anterior part of the forebrain lateral ventricles and the subgranular
zone (SGZ) within the hippocampus, corresponding to the inner layer
of the dentate gyrus [9–11]. New neurons and glia continue to be
generated within these restricted regions of the adult mammalian
brain [12]. Evidence that neurogenesis persists in the CNS of the adult
mammalian brain (albeit in restricted domains) has changed our
perception of the cell of origin with respect to neural neoplastic
transformation [13,14].
1.3. Telomere and telomerase status during normal and
dysregulated neurogenesis
In virtually all types of malignant cells, unlimited replicative
potential is conferred in considerable part, by the maintenance of
telomere length above a critical minimum threshold. Telomeres
(derived from the Greek telos, meaning end and meros, a component)
are a complex of guanine-rich repeat sequences and associated
proteins that form a loop structure which caps all eukaryotic
chromosome termini [15] and prevents chromosomes from improper
recombination, nuclease degradation and end fusions, thereby
contributing to genomic stability. Due to incomplete replication of
lagging-strand synthesis at each mitotic division (‘end-replication
problem’) [16], telomeres progressively shorten, a phenomenon that
provides a molecular basis of cellular aging and hints at a primitive
tumour-suppressor mechanism [17]. In germ cells and cancer cells,
unlimited proliferative capacity is achieved through the addition of
telomeric repeats by the telomerase holoenzyme. Telomerase is a
ribonucleoprotein consisting of an RNA subunit (TR) which provides
an intrinsic template for the synthesis of de novo telomeric repeats in
a reaction catalyzed by its enzymatic component (TERT) [18].
NSCs from different regions of the brain have different proliferative
capacities and varying abilities to generate astrocytes, oligodendro-
cytes and neurons [19,20]. This may be reﬂected in the level of
telomerase activity and telomere length reserve within cells fromdifferent neuro-anatomical compartments, in particular regions of
high neurogenic activity such as the SVZ and SGZ [21]. Telomerase-
mediated telomere homeostasis is therefore a likely key factor in brain
plasticity throughout development and adulthood.
There is a suggestion here that a fuller understanding of the
replicative histories of cells within tumour hierarchical compartments
may provide clues as to the cancer cell of origin for a given brain
neoplasm. Indeed telomerase activity has been detected in a growing
number of brain tumours in the past decade [22–27]. With pre-clinical
and clinical advances in telomerase-therapeutics for cancer, there is
anticipation that this will impact upon paediatric and adult tumours
of the CNS.
1.4. Brain tumourigenesis and tumour heterogeneity
A developmental relationship between tissue stem cells and cancer
cells has been proposed over 50 years ago [28,29]. However the
pioneering demonstration of ‘cancer stem cells’ in human cancer was
ﬁrst made in leukaemia [30,31]. From this initial discovery in
hematopoietic tumours, evidence from most solid cancers studied
deﬁnes restricted subsets of tumourcells that share characteristics of the
corresponding normal tissue stem cells [32–36]. This paradigm includes
prospective isolation of a minority population of brain tumour cells,
based on the expression of the cell surface antigen CD133, known to be
highly expressed in normal neural stem cells. These putative brain
cancer stem cells were isolated from medulloblastoma, pilocytic
astrocytoma, glioblastoma multiforme and anaplastic ependymoma
and possessed a marked capacity for self-renewal (evidenced by the
formation of ﬂoating aggregates termed tumourspheres), proliferation
and differentiation [37–40]. Crucially, only the CD133+ fraction was
capable of tumour initiation upon orthotopic transplantation into non-
obese diabetic severe combined immunodeﬁcient (NOD-SCID) mouse
brain [41]. The CD133+ fraction produced a tumour that generated a
phenocopyof the original tumour and couldbe serially transplanted into
secondary recipients, providingevidence of self-renewal capacity invivo
[41]. Our growing understanding of the hierarchical organization of the
functional compartments in renewing brain tissues provides a theore-
tical and technical framework upon which to base falsiﬁable questions
regarding brain tumour initiation and cell of origin.
1.5. A multidisciplinary approach to a new synthesis
Recent compelling evidence demonstrate that the brain, similar to
other organs in which cancers arise, harbours a stem cell population
that can give rise to differentiated CNS cells. Prospective identiﬁcation
of neural cells with shared stem cell-like properties which are capable
of initiating tumours in vivo and that are phenocopies of the original
tumour, provides a new synthesis in brain tumour research. The
cellular architecture of brain tumours may thus represent a distorted
mimicry of normal developmental neuro-biology. This concept,
coupled with an increasing understanding of the immortal status of
transformed neural cells, particularly with respect to aberrant
telomerase activity and the maintenance of critically short telomeres,
will arguably provide an experimental basis to better understand and
delineate cancer changes that are causal and consequential with
respect to tumour hierarchy and tumour initiation. This review
encourages a consilient approach to investigate telomere/telomerase
neurobiology and brain tumour stem cells within a neurodevelop-
mental core.
2. Developmental neurobiology
2.1. Neuroepithelial cells, radial glia and early neurogenesis
The origin of all CNS cells can be traced to a single layer of
embryological cells, which constitute the neuroepithelium. The edges
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rise to the ventricular system and spinal canal. Initially, neuroepithe-
lial cells divide symmetrically in order to increase the stem cell pool;
thereafter these highly plastic cells proliferate and acquire regional
identities in a spatial-temporal manner [10]. It is likely that neuro-
epithelial cells differentiate directly into radial glial cells in the
embryonic ventricular zone [42], although this has not been
conﬁrmed experimentally. Some recent supporting evidence is
presented by the derivation of both neuroepithelial cells and radial
glia from human embryonic stem cells; the course of differentiation
(with respect to morphology change and lineage-speciﬁc marker
expression) followed a temporal manner with neuroepithelial cells
generated ﬁrst, followed later by radial glial cells and ﬁnally mature
neurons [43].
The fate and function of a radial glial cell varies considerably from
region to region in the CNS. It had long been accepted that radial glia
are both astroglial progenitors [44,45] and oligodendrocyte progeni-
tors [46,47], but recent evidence has demonstrated that radial glia
produce most of the cortical neurons [48–50]. Radial glial cells thus
serve as neural stem/progenitor cells for the majority of neurogenesis
and gliogenesis in the developing brain and gives rise to the
astrocytic-like neural stem cells of the adult brain [48–52]. Whether
radial glia transform directly into an adult multipotent neural stem
cell or progenitor, or whether they ﬁrst differentiate into an
intermediate cell type, is unknown (see question marks, Fig. 1). This
concept of early neurogenesis is in dramatic contrast from the long-
held view that embryonic, post-natal and adult NSCs are discrete
unrelated populations.
2.2. Multipotent neural stem cells and neurogenesis in the mature CNS
Although widespread neurogenesis is restricted to the embryonic
period, a limited number of neural stem cells persist throughout
adulthood and are restricted mainly to two neurogenetic domains
[13,14,53]. The largest of these regions is the mammalian SVZ situated
throughout the lateral walls of the forebrain lateral ventricles [11]. A
similar hierarchical neurogenetic system exists in the SGZ, an area
corresponding to the dentate gyrus of the hippocampal granular layer
[54,55]. Stem cell progeny generated within these regions populate
the growing CNS parenchyma, later differentiating into mature
neuronal and glial fates, speciﬁed in a precise spatial-temporal
manner [56]. Cells that express the intermediate ﬁlament astroglial
marker, glial ﬁbrillary acidic protein (GFAP), have been identiﬁed as
putative adult neural stem cells in this region, also known as Type B
cells [57,58] (Fig. 1). The embryonic origin of Type B cells has been
conﬁrmed using in vivo lineage tracing techniques and shows that
adult subventricular cells are not related to embryonic subventricular
precursors, but embryonic ventricular radial glia [59,60].
Further support of the astrocytic nature of NSCs has been
conﬁrmed in experiments in which GFAP+ cells were conditionally
ablated in the brain of adult mouse, resulting in near complete loss of
neurogenesis [61,62]. Type B cells are proposed to be relatively
quiescent with a cell cycle duration of ∼24 h and constitute a small
fraction of the total astrocytic population in the SVZ [57]. Pioneering
experiments retrospectively viewed, adds support to this notion;
Reynolds andWeiss in 1992, isolated a small population of cells (b0.1%
of total cells) from the adult striatum that could proliferate and
generate multiple clones of cells in free-ﬂoating clusters in vitro called
neurospheres [63]. It is worth noting that even with current reﬁned
methods to isolate neural stem cells using the neurosphere assay, the
stem cell content is variable; although Type B and Type C cells can
produce neurospheres, not all cells within the neurosphere express
stem cell markers [58,64].
Multipotent Type B astrocyteswithin the SVZ give rise to fast-cycling
transiently amplifying precursor cells called Type C precursors, which in
turn generate either mitotically active Type A neuroblasts or terminallydifferentiated mature glia (astrocytes, oligodendrocytes). Type A
neuroblasts migrate towards the olfactory bulb where they integrate
as mature neurons (Fig. 1). Similarly, Type B astrocytes in the SGZ
produce intermediate Type D precursors which give rise to Type G
granule neurons [65]. Over the course of development, NSCs not only
feature altered morphology but also exhibit changes to gene expression
proﬁles in a temporal-speciﬁc manner [66]. This expression proﬁle may
underlie an intrinsic developmental program as progenitors grown in
culture generate progeny at certain times, similar to progenitors in vivo
[67]. In addition to GFAP, Type B cells express other intermediate
ﬁlaments such as vimentin and nestin. As NSCs differentiate along
developmental pathways, neuronal-speciﬁc (polysialylated neural cell
adhesion molecule (PSA-NCAM), microtubule-associated protein 2
(MAP2), neuroﬁlament protein, tyrosine hydroxylase) and glial-speciﬁc
markers (O4 monoclonal antibody that recognizes the sulfatides and
myelin basic protein (MBP)) are expressed in late-amplifying and
mature cell compartments [68] (Fig. 1).
2.3. The role of telomeres and telomerase during neurogenesis
Most studies aimed at understanding the nature of NSCs with
respect to self-renewal, proliferation and differentiation, focus on
external cues such as secreted growth factors [69,70]. Few studies
have addressed the role of intrinsic mechanisms regulating NSC
behaviour [71]. Chromosome integrity is essential for cell viability,
therefore highly proliferative cell types such as tissue stem cells,
require active telomere maintenance strategies to proliferate indeﬁ-
nitely or at least long enough for the host organism to reach
reproductive age. The role of telomere and telomerase dynamics in
NSC compartments has scarcely been addressed. In the mouse, high
levels of TERT and TERC (murine telomerase RNA subunit) mRNA are
present in the developing neural tube as early as E10.5 [72]. Both
telomerase subunits continue to be expressed in different regions of
the developing murine CNS and correlates with the proliferation of
neural progenitors [73–75]. This suggests a role for telomerase during
speciﬁcation of neural cell types. Consistent with our knowledge of
neurogenetic regions of the adult brain, telomerase activity has been
shown in neural precursor cells isolated from the SVZ and hippo-
campus in adult mice [21]. With reference to stem cell populations in
other tissues, the current working hypothesis states that telomerase
activity in NSCs (and actively proliferating early neural precursors)
may combat induced telomere shortening upon mitotic division.
However, human progenitor cells isolated from the developing cortex
which exhibit low/absent levels of telomerase activity, undergo
decreased neurogenesis and eventually enter replicative senescence
in vitro [76]. These ﬁndings are corroborated by studies in other
tissues where low levels of telomerase activity have been found in
tissue stem cells such as hematopoietic, skin, intestinal crypt and
pancreas [77–80]. In all these cases, telomerase activity is insufﬁcient
to completely prevent telomere loss and senescence. Rather, telome-
rase in tissue stem cells may slow the rate of telomere shortening and
maintain a replicative reserve pre-determined for the tissue stem cell
in question. It is difﬁcult to argue that this phenomenon is not a
primitive tumour-suppressor mechanism and perhaps one that
predates protein-mediated tumour suppression.
Telomere attrition dramatically impairs the in vitro proliferation of
adult NSCs isolated from the SVZ of telomerase-deﬁcient mice, but not
that of embryonic NSCs, even though the latter exhibited critically
shortened telomeres. This is consistent with a recent report describing
telomerase levels as high in embryonic cortical neural progenitor cells,
but low in newly generated neurons and mature neurons [81].
Collectively these results hint at intrinsic differences in the protective
states between adult and embryonic NSCs, with respect to chromo-
somal stability and response to dysfunctional telomeres [82]. A
comprehensive understanding of how the regulation of telomeres/
telomerase is tightly linked to cell cycle regulation in tissue stem cells
Fig. 1. Stem cell theory for the role of telomeres and telomerase in postnatal neurogenesis and cancer. Radial glial cells (RG, green box) differentiate from embryonic neuroepithelial progenitors at the beginning of neurogenesis and are
distinguished by the expression of astroglial lineage markers in the neonatal brain. Within the constitutively active germinative layers associated with the anterior part of the forebrain lateral ventricles (SVZ, shown here) and corresponding to
the inner layer of the dentate gyrus within the hippocampus (SGZ, not shown), radial glia give rise to adult multipotent neural stem cells (Type B astrocytes, dark blue circle). At later developmental stages, radial glial cell division can also
produce ependymal cells (light blue circle) that constitute the epithelia lining the ventricular system of the brain and spinal cord. Type B neural stem cells retain markers of radial glia, have high levels of telomerase activity and may have
longer telomeres relative to mature neurons or glia. During postnatal neurogenesis, neural stem cells differentiate and give rise to fast-cycling early transit amplifying progenitors (Type C putative precursors, orange circle), which can give rise
to terminally differentiated mature glia (astrocytes, oligodendrocytes) or late transit amplifying progenitors (Type A migrating neuroblasts, yellow star) that are committed to a mature neuronal fate and that express neuronal-speciﬁc
markers. As multipotent neural stem cells differentiate into mature functional neurons and glia, the capability to leave the stem cell perivascular niche and regenerate neural tissue is decreased. This is due in considerable part to telomere
shortening across time. Decreased mobilization of stem cells in aged neural tissue is likely to be consequential of senescence (replicative and stress-induced) and apoptosis. There is an increasing awareness that the growth and recurrence of
brain tumours may be due to a transformed CNS cell type with shared characteristics to a somatic neural stem cell (self-renewal, differentiation) and endowed with tumour-initiating ability. These ‘brain tumour stem cells’ may arise in vivo
from a transformed neural stem cell or from an early neural progenitor that acquires the ability to self-renew through mutation. Abbreviations: SC, stem cell; ET, early transit amplifying progenitor; LT, late transit amplifying progenitor; EP,
ependymal cells; SVZ, subventricular zone; SGZ, subgranular zone; GFAP, glial ﬁbrillary acidic protein; PSA-NCAM, polysialylated neural cell adhesion molecule; MAP2, microtubule-associated protein 2; O4, monoclonal antibody that
recognizes the sulfatides; MBP, myelin basic protein. Blue rectangles represent stem cell/progenitor populations; red rectangles represent terminally differentiated cell types.
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regulation is perturbed.3. Cellular immortality and tumour initiation
3.1. Telomeres and telomerase in brain tumours
Tumourigenesis involves multiple oncogenic insults which collec-
tively deﬁne the tumour phenotype. Experimental data from cultured
human ﬁbroblasts indicate that cells must bypass two checkpoints,
mortality stage 1 (M1), regarded as cellular senescence and mortality
stage 2 (M2), characterised by widespread apoptosis, prior to
immortalization and unlimited replicative potential [83]. Reactivation
of hTERT is a crucial determinant of cellular immortalization and if
accompanied by inactivation of tumour-suppressor genes and/or
activation of cellular oncogenes, can subsequently result in neoplastic
formation. Telomerase-mediated telomere maintenance is evident in
virtually all types of malignant cells, and ∼90% of tumours show
evidence of up-regulated telomerase [84,85]. Brain tumours in which
telomerase activity has been detected include glioblastoma, anaplastic
astrocytoma, oligodendroglioma, primitive neuro-ectodermal
tumours, medulloblastoma and ependymoma [23–26]. These data
indicate that hTERT reactivation or overexpression is an essential
event for tumour progression in CNS tumours. The role of hTERT may
not be restricted to addition of telomere repeats as mouse TERT has
been shown to promote cell survival (prevents apoptosis) in neurons,
a function that does not require the telomerase RNA subunit [86]. This
extracurricular TERT function may contribute to cancer developmentFig. 2. Proposed role for telomerase activity and telomere stabilization in brain tumour in
harbours regions that retainmitotic activity throughout adulthood, in particular the subventr
these regions through cell cycle re-entry and differentiation of tissue-speciﬁc stem cells, giv
neural progenitors and mature cell types through intact functional cell cycle and senescence
tumour suppressors, oncogenic insults, checkpoint failure and chromosome instability, i
transformed neural stem cell (‘brain tumour stem cell’). It is unclear whether mutational ev
brain tumour progenitor cell and ‘mature’ malignant neural cell, or whether additional mu
(aberrantly) differentiates, telomere shortening is likely to occur; however due to hTERT act
cell would be expected to be stabilized. Although depicted here as arising in a neural stem ce
scenario, the progenitor cell may acquire the capacity to self-renew through mutation, incrand aging independently of telomere lengthening and telomerase
activity.
In a comprehensive analysis of telomere length, themajorityof grade
II astrocytomas, anaplastic astrocytomas and glioblastomas with
telomerase activity, exhibited signiﬁcantly shorter mean telomere
lengths relative to corresponding tumours with undetectable telome-
rase activity and to normal brain tissue. Similarly, all primitive neuro-
ectodermal tumours exhibited shorter telomere lengths relative to
normal brain tissue [24]. Recentﬁndings fromour own laboratory reveal
that paediatric glioblastoma multiforme and ependymoma, tumours of
glial origin, have signiﬁcantly longermean telomere length than thoseof
supratentorial neuroectodermal tumours and medulloblastoma,
tumours of neuroectodermal origin. This highlights the consideration
required for telomere length with respect to duration/course of
treatment when using anti-telomerase drugs which are predicted to
exert their effects upon telomere shortening (Rahman R et al.
unpublished data). The concurrent shortening of telomeres with
telomerase reactivation/overexpression supports a hypothesis that
telomerase is required to maintain both minimum length and a termi-
nal capping structure at a subset of critically shortened telomeres [87].
The perspective presented by the stem cell origin of brain tumours
implies that the genetic alterations that lead to cancer, accumulate in
NSCs rather than mature neural cells. As NSCs would already exhibit
telomerase activity, one would predict the enzyme to be over-
expressed rather than reactivated. Whether telomerase activity
increases during later stages of carcinogenesis is unclear [88]. Similar
to self-renewing tissues where hTERT expression is insufﬁcient to halt
progressive telomere shortening, telomere shortening may continue
within a proliferating transformed neural stem cell. However, aberrantitiation and propagation. (Normal developmental neurogenesis) The postnatal brain
icular zone (SVZ) and subgranular zone (SGZ). Mature neurons and glia are generated in
ing rise to neural lineage-restricted progenitors. Faithful cell division is safeguarded in
checkpoints. (Dysregulated developmental neurogenesis) hTERT overexpression, loss of
ncrease the tumourigenic potential of the tissue stem cell, ultimately resulting in a
ents at tumour-initiation are necessary and sufﬁcient to propagate differentiation to a
tational events drive progression of the tumour. As the transformed neural stem cell
ing on critically shortened telomeres, telomere length in the (mature) malignant neural
ll, it remains plausible that the tumour cell of origin is a neural progenitor; in the latter
easing the propensity to initiate a tumour.
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both with respect to telomere length and 3′ telomere capping
structure (Fig. 2). Elucidation of telomerase levels and telomere
length within different neurogenetic subsets will inﬂuence strategies
to target telomerase in brain cancer.
3.2. The brain tumour stem cell paradigm
An acceptance of tumour hierarchical organization readily leads to
a developmental-centred view of tumourigenesis, where brain
tumours represent aberrantly differentiated tissue, in turn reﬂecting
dysregulated neurogenesis. The stem cell paradigm for brain tumours
presents tumour-initiating events as occurring within the genome of a
cellular entity with neural stem cell-like properties.
The identiﬁcation of brain tumour stem cells was prospectively
demonstrated by Peter Dirks and colleagues using cells derived from
glioblastoma and medulloblastoma. As few as 100 cells sorted
positively for the cell surface antigen CD133, were capable of initiating
inﬁltrative tumours upon orthotopic transplantation into SCID mice
whereas injection of 100,000 CD133− cells failed to initiate tumours
[41]. In a later study, tumour stem cells isolated from ependymoma
manifested a radial glial phenotype with CD133+/Nestin+/RC2+/
BLBP+ positivity conﬁrmed to be tumourigenic [40].
It is important to note that a deﬁnitive demonstration of tumour
stem cells in the brain is lacking as CD133 enriches for, rather than
deﬁnitively identiﬁes, cancer stem cells. This caveat has been em-
phasized with recent studies showing that CD133− glioblastoma cells
have tumour-initiating ability [89,90]. In addition, it is the CD133+/
Nestin+/RC2-/BLBP− phenotype that exhibited a tumourigenic
phenotype in medulloblastoma in contrast to the CD133+/Nestin+/
RC2+/BLBP+ phenotype in ependymoma [40], suggesting that the
characteristics of these two subsetsmay reﬂect different cell of origins.
Clearly stem-like properties in a tumour cell cannot be taken as direct
evidence for neoplastic transformation occurring in a neural stem cell
that originates in a zone of active neurogenesis. The cancer stem cell
hypothesis and the cellular origin of cancer are distinct paradigms. It is
conceivable that a neural progenitor or mature cell could give the
appearance of ‘stemness’ upon neoplastic transformation (Fig. 2).
An alternative focus is that of molecular events that permit tumour
initiation rather than on the cell type that initiated the tumour. The
cancer stem cell hypothesis predicts mechanistic similarities between
self-renewal of cancer stemcells andnormal stemcells. Inbrain tumours
there is particular interest in the Notch [91,92] and Sonic-hedgehog
[93,94] pathways, as these have been shown to be important for normal
stem cell self-renewal as well as dysregulated growth in cancer.
Overexpression of Notch receptors and their ligands Delta-like 1
(DLK1) and Jagged 1 (JAG1) correlates with the proliferative capacity
of human glioma cells, implicating Notch as a positive effector of self-
renewal in adult neural stem cells [95]. Furthermore, overexpression of
Notch-2 intracellular domain protein increases proliferation of medul-
loblastoma cell lines [96], whereas medulloblastoma growth is
suppressed by the known Notch inhibitor, γ-secretase [97]. Similarly
Sonic Hedgehog (SHH) and its downstreameffectors, glioma-associated
homologue 1 (GLI1), GLI2 and GLI3 have been shown to speciﬁcally
regulate self-renewal and neurogenesis within the external granular
layer of the post-natal cerebellum and to control proliferation of
precursorswithin the adult SVZ [98].Mutations in this pathway are thus
implicated in the initiation of medulloblastoma [99,100].
Another emerging concept is that brain tumour stem cells may
crucially be supported by a speciﬁc microenvironment which mimics
the neural vascular niche [101]. Differentiated neural cells or blood
vessel cells have been implicated as niche elements. CD133+
glioblastoma cells secrete increased levels of vascular endothelial
growth factor (VEGF) compared to CD133− counterparts, implicating
tumour stem cells as contributing to tumour angiogenesis [102].
However, whether the tumour stem cell niche differs from that of thebulk tumour population or whether it provides signals which govern
aberrant self-renewal is unclear. Future work will validate the pro-
position that the tumour stem cell niche represents an attractive
therapeutic target.
The cancer stem cell ﬁeld is at present contentious, in part due to
differing semantic interpretations. The ‘cancer stem cell’ term is often
applied to cells identiﬁed by varying methods and criteria. The danger
here is the application of the term to cells with no evidence of cancer-
initiating capacity. It is important to clarify what ‘brain tumour stem
cell’ refers to in the present context: these are cells which demonstrate
cancer-reinitiating ability upon orthotopic transplantation, with a
capacity to generate a phenocopy of the original tumour mass
(consisting both tumourigenic and non-tumourigenic cells); show
extensive self-renewal ability ex vivo and in vivo; demonstrate
aberrant multipotent differentiation; harbour karyotypic and/or
genetic alterations. At present, this does not exclude the possibility
of more committed progenitors or even mature cells reverting to a
stem-like phenotype and causing tumour-initiation in contexts that
differ from those imposed by the pre-mentioned strategies. For
example, it may be argued that the mouse may not represent a
physiologically relevant microenvironment for engraftment and
growth of human tumours, thus potentially resulting in an under-
estimation of cell types capable of tumour initiation.
4. Towards a new therapeutic outlook
The discovery of putative brain tumour stem cells and the growing
understanding of neurogenesis and cellular immortality, presents
both a novel cellular target and novel molecular targets within. Much
larger numbers of brain tumour samples and prospective multi-
parameter cell sorting are needed to determine whether the cancer
stem cell hypothesis is robust as well as to delineate patient subsets
within a particular brain tumour type. Do all tumours under a
common nomenclature reﬂect a common cell of brain cancer origin?
What are the implications for therapy if they do not? In addition,
evidence to date does not address whether the cell type conferring
self-renewal capacity through tumoursphere-formation in vitro is the
same cell type that initiates the neural tumour in vivo; these studies
involve tumour-initiating populations (heterogeneous) rather than
(homogenous) tumour-initiating cells. Similarly, it is important to
separate tumour-initiation and tumour-propagation; this may not
involve the same cell type as the tumour-propagating cell may be a
much differentiated progeny of the tumour-initiating cell. It is
conceivable therefore, that improved therapeutic efﬁcacy may be
achieved by targeting both the cell-type(s) which drives malignant
progression as well as that which initiates – and maintains the stem
cell pool of – the tumour.
Since telomerase activity has been detected in almost all advanced
brain tumours, the use of telomerase inhibitors may provide an
attractive approach to therapy. These may be most effective in
reducing the risk of relapse by targeting cancer stem cells. As normal
neural stem cells would be expected to have longer telomeres than
brain cancer stem cells, it follows that telomere depletion will be
spared in the normal stem cell pool [103,104]. There is a practical
consideration here with respect to telomere length: if anti-telomerase
approaches rely on telomere shortening for efﬁcacious results, then
the initial telomere length in the target cancer cell must be a consi-
deration. This invokes the brain tumour cell of origin once again, as
telomere dynamics reﬂect the mitotic history of highly proliferating
cells. Elucidation of telomere length and telomerase activity in subsets
of cells within the tumour hierarchy will enable a more targeted anti-
telomerase approach, perhaps in combination therapy. The identi-
ﬁcation of a greater array of surface markers will likely aid this
characterisation.
Key cell signalling pathways such as Notch and Sonic Hedgehog,
that are involved in the regulation of self-renewal in both normal and
Fig. 3. Brain tumour cells exhibit intrinsic resistance to current treatment modalities. The cancer stem cell hypothesis presents an attractive framework upon which to consider a
gestalt shift in treatment protocols for CNS tumours. (Top) Existing therapeutic regimes successfully achieve a substantial degree of tumour remission prior to tumour relapse fuelled
by a brain tumour population(s) with intrinsic resistance to therapy. There is increasing evidence that the resistant cell type is a neural stem-like cell with dysregulated self-renewal
or neural progenitor which has acquired aberrant self-renewal capabilities throughmutation. Mechanisms of tumour stem cell resistance are largely based on presumptions of shared
properties with neural stem cells; however evidence is beginning to emerge demonstrating that brain tumour stem/progenitor cells are intrinsically protected, relative to the bulk
tumour (yellow box). (Bottom) It is likely that a new therapeutic paradigmwill include chemosensitizers and cytotoxic agents that target the dysregulated pathways of neural stem/
progenitor cells and mechanisms that mediate resistance, such as ABC-drug transporters. Characterisation of telomere length/structure and telomerase activation levels in brain
tumour sub-compartments will reveal whether anti-telomerase therapy will be an attractive proposition for CNS tumours. To accomplish a durable response within this new
therapeutic paradigm, conventional cytotoxic agents would be used to de-bulk the tumour mass in a combinatorial strategy with agents for targeted therapy. Nevertheless, a number
of challenging, pertinent and often controversial biological questions surround the cancer stem cell paradigm (see section on The brain tumour stem cell paradigm).
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thorough understanding of the mechanisms of signal transduction in
each context, particularly with respect to gene expression levels will
determine whether disrupting self-renewal pathways in brain tumour
stem cells will spare normal neural stem cell pool function and result
in tumour growth inhibition.
In addition, better therapeutics will rely on a better understanding
of the intrinsic mechanisms of resistance in brain tumour cells. The
cancer stem cell hypothesis predicts that only tumourigenic cells are
resistant to therapy. Recent work studying radiation resistance
supports this idea as CD133+ glioma stem cells show preferential
activation of the DNA damage response upon radiation treatment
[102]. However, whether the same cell type that confers radio-
resistance is the same cell type that confers chemoresistance is
unknown. Tumour resistancemay also arise if brain tumour stem cells,
similar to normal stem cells, generally reside in a quiescent state
outside the cycle of division. Although direct evidence is lacking, if
shown to be correct, this would affect the rationale and approach of
drugs targeting telomerase and self-renewal pathways. In addition,
brain tumour stem cells may plausibly have high levels of ATP-binding
(ABC) drug transporters, which can protect cells from cytotoxic agents
[105]. This may result in the efﬂux of cytotoxic agents delivered to
tumour stem cells. If ABC transporters are shown to contribute to
tumour resistance, the next generation of chemotherapy regimes may
involve chemosensitizers in conjunction with agents that alter drug-
transporter activity.
Understanding the molecular and genetic basis of the cell type(s)
surviving multi-modal therapy will be crucial to our unwavering hope
of a curative response in brain cancer patients (Fig. 3). Is each factor
contributing to resistance, both necessary and sufﬁcient for tumourresistance? Or is coercion required involving all factors of resistance?
If the latter, will targeting one mechanism of resistance sufﬁce?5. Concluding remarks
The brain cancer stem cell paradigm without reference to
neurodevelopment and dysregulated cellular proliferation is perhaps
reductionist and oversimpliﬁed. The emerging concept of a close
relationship between developmental neurobiology, telomere/telo-
merase biology and brain cancer stem cells, encourages a consilient
approach to develop the next generation of brain cancer therapeutic
interventions. At one time disparate, these areas of investigative
biology should help determine the cellular culprit of particular brain
cancer types, both with respect to the cell type where neoplastic
transformation occurs and to the molecular events that permit it. If
these tumour-initiating cells are intrinsically resistant to conventional
therapeutic strategies, then a comprehensive characterisation of this
mechanism will allow more effective combination therapy to be
developed in the future.References
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